Merrimack Pharma: Annual Report 2014 (Merrimack) - Mar 8, 2015 - Anticipated patent expiry of principle and methods of co-targeting IGF-1R and ErbB3 in human disease in US, EU, Canada, Australia and Japan in 2030; Anticipated expiry of patent family covering compositions, methods of use, and disease indications in US, EU, Japan and ROW in 2032; Anticipated expiry of patents in US, EU and 9 other jurisdictions covering compositions, methods of use, disease indications and drug combination regimens related to MM-141 in 2033; Anticipated expiry of patent in 2035
Anticipated patent expiry • Oncology
|